



18th Executive Board

6 - 7 June 2013

WHO Headquarters, Salle A

Geneva, Switzerland

Resolution n°6

Support to HIV first line treatments

Having considered the Board document, *Towards increased and equitable access to quality HIV treatment: a multi-stakeholder collaboration to shape first-line HIV medicines markets*, prepared by the Secretariat in consultation with stakeholders;

The Board acknowledges the significant public health benefit of tenofovir-based regimens for the treatment of HIV, as will be recommended in the forthcoming 2013 World Health Organization HIV treatment guidelines. The Board recognizes the underlying market shortcomings that are contributing towards lower access to these regimens through higher prices, stock outs and delivery delays; as well as the need to intervene in this market quickly, ahead of the typical Global Fund grant reprogramming schedule.

Therefore, the Board agrees in principle to consider funding the intervention to a ceiling of 77 million USD, as described in the Board document, in collaboration with other key stakeholders.

The Board requests urgent PRC review of the proposal, and additional research to address key questions, such as funding flows, budget revision, and mechanism for providing in-country work and treatment shift. Following this, the Board requests an electronic vote on funding of this intervention by Q3 2013.

A handwritten signature in blue ink, appearing to read "P. Douste-Blazy". The signature is stylized and cursive.

Philippe Douste-Blazy
Chair of the UNITAID Executive Board